2016
Randomized, Controlled Trial of Intravenous Immunoglobulin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections
Williams KA, Swedo SE, Farmer CA, Grantz H, Grant PJ, D’Souza P, Hommer R, Katsovich L, King RA, Leckman JF. Randomized, Controlled Trial of Intravenous Immunoglobulin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections. Journal Of The American Academy Of Child & Adolescent Psychiatry 2016, 55: 860-867.e2. PMID: 27663941, DOI: 10.1016/j.jaac.2016.06.017.Peer-Reviewed Original ResearchConceptsPediatric autoimmune neuropsychiatric disordersIntravenous immunoglobulinAutoimmune neuropsychiatric disordersYale-Brown Obsessive Compulsive ScaleChildren's Yale-Brown Obsessive Compulsive ScaleStreptococcal infectionIVIG groupPlacebo groupObsessive-compulsive disorderClinical Global Impression improvement ratingNeuropsychiatric disordersDouble-blind infusionDouble-blind phaseSustained symptom improvementDouble-blind comparisonOpen-label treatmentPrimary outcome measureSevere obsessive-compulsive disorderCY-BOCS total scoreCross-reactive antibodiesIdentification of biomarkersCY-BOCS scoresObsessive Compulsive ScaleImmunomodulatory therapyControlled Trials
2015
Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials
Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Coughlin CG, Leckman JF, Bloch MH. Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials. Journal Of The American Academy Of Child & Adolescent Psychiatry 2015, 54: 728-736. PMID: 26299294, DOI: 10.1016/j.jaac.2015.06.011.Peer-Reviewed Original ResearchConceptsWorsening of ticsRisk of ticsAttention-deficit/hyperactivity disorderPlacebo-controlled trialNew onsetDuration of treatmentPsychostimulant usePsychostimulant medicationNew-onset ticsType of psychostimulantsParallel-group trialStratified subgroup analysisSide effect dataTreatment of childrenAge of participantsPlacebo groupAdverse eventsCrossover studyPsychostimulant treatmentTic symptomsRisk ratioSubgroup analysisFamily historyGroup trialsPubMed search
2013
N-Acetylcysteine in the Treatment of Pediatric Trichotillomania: A Randomized, Double-Blind, Placebo-Controlled Add-On Trial
Bloch MH, Panza KE, Grant JE, Pittenger C, Leckman JF. N-Acetylcysteine in the Treatment of Pediatric Trichotillomania: A Randomized, Double-Blind, Placebo-Controlled Add-On Trial. Journal Of The American Academy Of Child & Adolescent Psychiatry 2013, 52: 231-240. PMID: 23452680, PMCID: PMC3745012, DOI: 10.1016/j.jaac.2012.12.020.Peer-Reviewed Original ResearchConceptsN-acetylcysteinePharmacological interventionsPediatric trichotillomaniaBenefit of NACBehavioral therapySecondary outcome measuresTreatment of childrenClinician-rated improvementMassachusetts General HospitalTreat populationPlacebo groupPrimary outcomeNAC groupGeneral HospitalOutcome measuresTreatment respondersSecondary measuresPlaceboTreatment assignmentTrichotillomaniaLinear mixed modelsTrialsSignificant differencesChildrenTherapy
2011
Risperidone-Related Improvement of Irritability in Children with Autism Is not Associated with Changes in Serum of Epidermal Growth Factor and Interleukin-13
Tobiasova Z, van der Lingen KH, Scahill L, Leckman JF, Zhang Y, Chae W, McCracken JT, McDougle CJ, Vitiello B, Tierney E, Aman MG, Arnold LE, Katsovich L, Hoekstra PJ, Volkmar F, Bothwell AL, Kawikova I. Risperidone-Related Improvement of Irritability in Children with Autism Is not Associated with Changes in Serum of Epidermal Growth Factor and Interleukin-13. Journal Of Child And Adolescent Psychopharmacology 2011, 21: 555-564. PMID: 22070180, PMCID: PMC3279715, DOI: 10.1089/cap.2010.0134.Peer-Reviewed Original ResearchConceptsMedication-free subjectsEpidermal growth factorHealthy controlsInflammatory markersIL-13IL-1 receptor antagonistGrowth factorSerum inflammatory markersChemoattractant protein-1Placebo groupClinical improvementBaseline visitIL-17Serum levelsCytokine concentrationsInflammatory moleculesSerum concentrationsClinical trialsHealthy subjectsIL-1Interleukin-13RisperidoneAltered levelsProtein 1Diagnosis of autism
2001
A Placebo-Controlled Study of Guanfacine in the Treatment of Children With Tic Disorders and Attention Deficit Hyperactivity Disorder
Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E, Arnsten AF, Cohen DJ, Leckman JF. A Placebo-Controlled Study of Guanfacine in the Treatment of Children With Tic Disorders and Attention Deficit Hyperactivity Disorder. American Journal Of Psychiatry 2001, 158: 1067-1074. PMID: 11431228, DOI: 10.1176/appi.ajp.158.7.1067.Peer-Reviewed Original ResearchConceptsAttention deficit hyperactivity disorderWeeks of treatmentPlacebo groupTic disordersGuanfacine groupDeficit hyperactivity disorderClinical Global Improvement ScaleHyperactivity disorderSafety of guanfacineGlobal Improvement ScaleDouble-blind conditionsTreatment of childrenMedication-free subjectsDose adjustmentBlood pressureADHD Rating ScaleDisorders ClinicWeek 4Mean improvementEffective treatmentImprovement ScaleGuanfacinePlaceboTic severityContinuous Performance Test